Canaccord speculates on takeout prices for ArthroCare

|About: ArthroCare Corporation (ARTC)|By:, SA News Editor

"We believe the stock will trade less on fundamentals and more on the take-out potential, [so] we once again put pen to paper to provide clarity on what we feel the different buyers are willing/able to pay," Canaccord says, regarding the outlook for ArthroCare (ARTC +18.8%) in the wake of the DPA announced Tuesday.

Analyst William Plovanic says the shares could be valued at "above $55 for an acquirer that planned on keeping most infrastructure."

For potential suitors with "existing infrastructure in sports med and ENT," Plovanic sees $80+.